Adjuvant AC Followed by Albumin-bound Paclitaxel Versus AC Followed by Taxanes in Breast Cancer: a Prospective, Multi-center, Real-world Study

NCT05287308 NA NOT_YET_RECRUITING

This is a prospective, multi-center, real-world study designed to evaluate the efficacy and safety of albumin-bound paclitaxel versus paclitaxel or docetaxel in adjuvant treatment of breast cancer.

Details

Lead sponsor	Chinese Academy of Medical Sciences
Phase	NA
Status	NOT_YET_RECRUITING
Enrolment	500
Start date	2022-03
Completion	2027-09

Conditions

• Breast Cancer

Interventions

• doxorubicin
• epirubicin
• pirarubicin
• cyclophosphamide
• albumin-bound paclitaxel
• paclitaxel
• docetaxel

Primary outcomes

• 5-year invasive disease-free survival (IDFS) rate — up to 60 months
  Invasive disease free survival was defined as the time from enrollment until the date of first occurrence of one of the following events: invasive ipsilateral breast tumor recurrence, local/regional invasive recurrence, distant recurrence (including first metastasis), invasive contralateral breast cancer, second primary invasive cancer (nonbreast, not including squamous or basal cell skin cancers, or new in situ carcinomas of any site), or death from any cause. 5-year IDFS rate is thepercentage of participants with IDFS from enrollment through 5 years.

Countries

China